Centessa Culls Early-Stage Asset For Inherited Disorder

Centessa Pharmaceuticals plc CNTA has decided to discontinue the development of ZF874 following a recent report of an adverse event involving elevated liver enzymes (AST/ALT) in a PiMZ subject dosed with 5 mg/kg in the Phase 1 study.
ZF874, a pharmacological chaperone designed to rescue the folding of the Z variant of alpha-1-antitrypsin (A1AT), was in a Phase 1 study to treat AATD.
As previously reported in November 2021, elevated liver enzymes were observed in a subject dosed with 15 mg/kg BID of ZF874 in the first cohort of patients within Part B of the Phase 1 study.
Based on the results observed, the company concluded that ZF874 was unlikely to achieve the desired target product profile.
The company remains on track to initiate registrational studies for SerpinPC for Hemophilia B in the second half of this year. It looks forward to initiating clinical trials with LB101 (PD-L1xCD47) for solid tumors after planned IND filing late this year.
Centessa ended the June quarter with cash and cash equivalents of $484.2 million, sufficient to fund operations into 2026.
Price Action: CNTA shares closed 3.28% lower at $5.01 on Tuesday.

Earnings Calendar